Scarica l'app Stockscreener
1.04
1.89%
-0.02
Femasys Inc Borsa (FEMY) Ultime notizie
The Latest Analyst Ratings For Femasys - Benzinga
Femasys Announces Peer-Reviewed Publication of Positive - GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment - Yahoo Canada Finance
Femasys price target lowered to $8 from $10 at Chardan - MSN
Femasys Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Femasys Inc. (FEMY) Quarterly 10-Q Report - Quartzy
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates - MSN
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - The Manila Times
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides - The Bakersfield Californian
Femasys Sales Surge 127% as Boston IVF Partnership, FDA Clearance Fuel Growth | FEMY Stock News - StockTitan
Femasys to Exhibit at the Annual AAGL 2024 Global Conference - GlobeNewswire
FEMYFemasys Inc. Latest Stock News & Market Updates - StockTitan
Femasys Partners with Boston IVF to Expand Access to Novel Fertility Treatment - Femtech Insider
Femasys secures new patent for FemBloc birth control By Investing.com - Investing.com South Africa
Femasys issued U.S. patent covering FemBloc device - MSN
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control - GlobeNewswire
Femasys secures new patent for FemBloc birth control - Investing.com
The 10 Best Booths from ASRM 2022 - Exhibitor Online
Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed - GlobeNewswire
Femasys Advances in Women’s Health Innovation - TipRanks
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program - GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Femasys Receives Second Order from Spain Partners After - GlobeNewswire
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments - StockTitan
Femasys announes infertility clinic customers from coast to coast - TipRanks
Femasys Announces Infertility Clinic Customers from Coast to Coast - GlobeNewswire
H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution - Investing.com India
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Femasys secures distribution partnerships for commercialization of FemaSeed - TipRanks
Femasys Secures Strategic Distribution Partnerships for - GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market - StockTitan
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device - Yahoo Finance
Items Tagged with 'Femchec' - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec - Investing.com India
Femasys Femchec receives FDA clearance - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec By Investing.com - Investing.com UK
Femasys Inc. Receives U.S. FDA Clearance to Market - GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check - StockTitan
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting - GlobeNewswire
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI - MSN
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
0.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):